Humoral and Cellular Immunity After Vaccination Against SARS-CoV-2 in Relapsing-Remitting Multiple Sclerosis Patients Treated with Interferon Beta and Dimethyl Fumarate
Background/Objectives: The impact of vaccines against SARS-CoV-2 on the immunity of patients with multiple sclerosis (PwMS) is still not fully known. Further clarification could help address medical concerns related to the use of immunosuppressive and immunomodulatory medications, known as disease-m...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-01-01
|
| Series: | Biomedicines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9059/13/1/153 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832589007699050496 |
|---|---|
| author | Marcin Bazylewicz Monika Zajkowska Monika Gudowska-Sawczuk Rafał Kułakowski Jan Mroczko Dagmara Mirowska-Guzel Joanna Kulikowska-Łoś Agata Czarnowska Barbara Mroczko Jan Kochanowicz Alina Kułakowska |
| author_facet | Marcin Bazylewicz Monika Zajkowska Monika Gudowska-Sawczuk Rafał Kułakowski Jan Mroczko Dagmara Mirowska-Guzel Joanna Kulikowska-Łoś Agata Czarnowska Barbara Mroczko Jan Kochanowicz Alina Kułakowska |
| author_sort | Marcin Bazylewicz |
| collection | DOAJ |
| description | Background/Objectives: The impact of vaccines against SARS-CoV-2 on the immunity of patients with multiple sclerosis (PwMS) is still not fully known. Further clarification could help address medical concerns related to the use of immunosuppressive and immunomodulatory medications, known as disease-modifying therapies (DMTs), in PwMS, as well as ensure adequate protection against severe outcomes of COVID-19. Therefore, the aim of our study was to evaluate the humoral and cellular immune response in PwMS treated with DMTs. Methods: The concentrations of IgG Spike (S) anti-SARS-CoV-2 antibodies and IgG Nucleocapsid (N) anti-SARS-CoV-2 antibodies, as well as interferon-gamma <i>(IFN-</i>γ) titers were analyzed in PwMS groups treated with dimethyl fumarate (DMF), interferon beta (IFN), and healthy control group. Results: Almost 100% of PwMS experienced seroconversion, which resulted from either vaccination and/or prior infection. Additionally, there were no significant differences between the study and control groups in terms of IgG (S) and (N) anti-SARS-CoV-2 antibody levels. However, interferon-gamma titers were lower in both PwMS groups, which may indicate adequate humoral and decreased cellular response to the examined PwMS. Additionally, after the division of the whole study group into two subgroups according to the time since the last vaccination, IgG (S) anti-SARS-CoV-2 and <i>IFN-</i>γ concentrations were significantly lower in the case of patients who were immunized more than 200 days before sample collection. No differences were observed in the case of subgroups in which sample collection was less than 200 days after vaccination when compared to the control group. Conclusions: This could indicate a time-related decrease in immunity in PwMS treated with DMTs. |
| format | Article |
| id | doaj-art-c7bd7853afa54ef3b92ec0b064a43ade |
| institution | Kabale University |
| issn | 2227-9059 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomedicines |
| spelling | doaj-art-c7bd7853afa54ef3b92ec0b064a43ade2025-01-24T13:24:12ZengMDPI AGBiomedicines2227-90592025-01-0113115310.3390/biomedicines13010153Humoral and Cellular Immunity After Vaccination Against SARS-CoV-2 in Relapsing-Remitting Multiple Sclerosis Patients Treated with Interferon Beta and Dimethyl FumarateMarcin Bazylewicz0Monika Zajkowska1Monika Gudowska-Sawczuk2Rafał Kułakowski3Jan Mroczko4Dagmara Mirowska-Guzel5Joanna Kulikowska-Łoś6Agata Czarnowska7Barbara Mroczko8Jan Kochanowicz9Alina Kułakowska10Department of Neurology, Medical University of Bialystok, 15-276 Bialystok, PolandDepartment of Neurodegeneration Diagnostics, Medical University of Bialystok, 15-269 Bialystok, PolandDepartment of Biochemical Diagnostics, Medical University of Bialystok, 15-269 Bialystok, PolandDepartment of Clinical and Experimental Pharmacology, Faculty of Medicine, Medical University of Warsaw, 02-091 Warsaw, PolandDepartment of Neurodegeneration Diagnostics, Medical University of Bialystok, 15-269 Bialystok, PolandDepartment of Clinical and Experimental Pharmacology, Faculty of Medicine, Medical University of Warsaw, 02-091 Warsaw, PolandDepartment of Neurology, Medical University of Bialystok, 15-276 Bialystok, PolandDepartment of Neurology, Medical University of Bialystok, 15-276 Bialystok, PolandDepartment of Neurodegeneration Diagnostics, Medical University of Bialystok, 15-269 Bialystok, PolandDepartment of Neurology, Medical University of Bialystok, 15-276 Bialystok, PolandDepartment of Neurology, Medical University of Bialystok, 15-276 Bialystok, PolandBackground/Objectives: The impact of vaccines against SARS-CoV-2 on the immunity of patients with multiple sclerosis (PwMS) is still not fully known. Further clarification could help address medical concerns related to the use of immunosuppressive and immunomodulatory medications, known as disease-modifying therapies (DMTs), in PwMS, as well as ensure adequate protection against severe outcomes of COVID-19. Therefore, the aim of our study was to evaluate the humoral and cellular immune response in PwMS treated with DMTs. Methods: The concentrations of IgG Spike (S) anti-SARS-CoV-2 antibodies and IgG Nucleocapsid (N) anti-SARS-CoV-2 antibodies, as well as interferon-gamma <i>(IFN-</i>γ) titers were analyzed in PwMS groups treated with dimethyl fumarate (DMF), interferon beta (IFN), and healthy control group. Results: Almost 100% of PwMS experienced seroconversion, which resulted from either vaccination and/or prior infection. Additionally, there were no significant differences between the study and control groups in terms of IgG (S) and (N) anti-SARS-CoV-2 antibody levels. However, interferon-gamma titers were lower in both PwMS groups, which may indicate adequate humoral and decreased cellular response to the examined PwMS. Additionally, after the division of the whole study group into two subgroups according to the time since the last vaccination, IgG (S) anti-SARS-CoV-2 and <i>IFN-</i>γ concentrations were significantly lower in the case of patients who were immunized more than 200 days before sample collection. No differences were observed in the case of subgroups in which sample collection was less than 200 days after vaccination when compared to the control group. Conclusions: This could indicate a time-related decrease in immunity in PwMS treated with DMTs.https://www.mdpi.com/2227-9059/13/1/153COVID-19SARS-CoV-2vaccinemultiple sclerosishumoralcellular |
| spellingShingle | Marcin Bazylewicz Monika Zajkowska Monika Gudowska-Sawczuk Rafał Kułakowski Jan Mroczko Dagmara Mirowska-Guzel Joanna Kulikowska-Łoś Agata Czarnowska Barbara Mroczko Jan Kochanowicz Alina Kułakowska Humoral and Cellular Immunity After Vaccination Against SARS-CoV-2 in Relapsing-Remitting Multiple Sclerosis Patients Treated with Interferon Beta and Dimethyl Fumarate Biomedicines COVID-19 SARS-CoV-2 vaccine multiple sclerosis humoral cellular |
| title | Humoral and Cellular Immunity After Vaccination Against SARS-CoV-2 in Relapsing-Remitting Multiple Sclerosis Patients Treated with Interferon Beta and Dimethyl Fumarate |
| title_full | Humoral and Cellular Immunity After Vaccination Against SARS-CoV-2 in Relapsing-Remitting Multiple Sclerosis Patients Treated with Interferon Beta and Dimethyl Fumarate |
| title_fullStr | Humoral and Cellular Immunity After Vaccination Against SARS-CoV-2 in Relapsing-Remitting Multiple Sclerosis Patients Treated with Interferon Beta and Dimethyl Fumarate |
| title_full_unstemmed | Humoral and Cellular Immunity After Vaccination Against SARS-CoV-2 in Relapsing-Remitting Multiple Sclerosis Patients Treated with Interferon Beta and Dimethyl Fumarate |
| title_short | Humoral and Cellular Immunity After Vaccination Against SARS-CoV-2 in Relapsing-Remitting Multiple Sclerosis Patients Treated with Interferon Beta and Dimethyl Fumarate |
| title_sort | humoral and cellular immunity after vaccination against sars cov 2 in relapsing remitting multiple sclerosis patients treated with interferon beta and dimethyl fumarate |
| topic | COVID-19 SARS-CoV-2 vaccine multiple sclerosis humoral cellular |
| url | https://www.mdpi.com/2227-9059/13/1/153 |
| work_keys_str_mv | AT marcinbazylewicz humoralandcellularimmunityaftervaccinationagainstsarscov2inrelapsingremittingmultiplesclerosispatientstreatedwithinterferonbetaanddimethylfumarate AT monikazajkowska humoralandcellularimmunityaftervaccinationagainstsarscov2inrelapsingremittingmultiplesclerosispatientstreatedwithinterferonbetaanddimethylfumarate AT monikagudowskasawczuk humoralandcellularimmunityaftervaccinationagainstsarscov2inrelapsingremittingmultiplesclerosispatientstreatedwithinterferonbetaanddimethylfumarate AT rafałkułakowski humoralandcellularimmunityaftervaccinationagainstsarscov2inrelapsingremittingmultiplesclerosispatientstreatedwithinterferonbetaanddimethylfumarate AT janmroczko humoralandcellularimmunityaftervaccinationagainstsarscov2inrelapsingremittingmultiplesclerosispatientstreatedwithinterferonbetaanddimethylfumarate AT dagmaramirowskaguzel humoralandcellularimmunityaftervaccinationagainstsarscov2inrelapsingremittingmultiplesclerosispatientstreatedwithinterferonbetaanddimethylfumarate AT joannakulikowskałos humoralandcellularimmunityaftervaccinationagainstsarscov2inrelapsingremittingmultiplesclerosispatientstreatedwithinterferonbetaanddimethylfumarate AT agataczarnowska humoralandcellularimmunityaftervaccinationagainstsarscov2inrelapsingremittingmultiplesclerosispatientstreatedwithinterferonbetaanddimethylfumarate AT barbaramroczko humoralandcellularimmunityaftervaccinationagainstsarscov2inrelapsingremittingmultiplesclerosispatientstreatedwithinterferonbetaanddimethylfumarate AT jankochanowicz humoralandcellularimmunityaftervaccinationagainstsarscov2inrelapsingremittingmultiplesclerosispatientstreatedwithinterferonbetaanddimethylfumarate AT alinakułakowska humoralandcellularimmunityaftervaccinationagainstsarscov2inrelapsingremittingmultiplesclerosispatientstreatedwithinterferonbetaanddimethylfumarate |